Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.

Park, C.W.; Lee, B.H.; Han, Hong-Ryul; Lee, C.H.; Ahn, Hye Kyung

doi:10.1111/j.1365-2133.2005.06474.x

Cited by 50 publications

(38 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These drugs inhibit the production of cytokines [37], the antigen-induced degranulation of mast cells and basophils [38, 39], and suppress allergic dermatitis [36, 40]. We confirmed that CsA inhibits the swelling of the ear lobe in both the immediate- and late-phase responses in our mouse model (fig.…”

Section: Discussionsupporting

confidence: 72%

Modification of the Picryl Chloride-Induced Allergic Dermatitis Model in Mouse Ear Lobes by 12-<i>O</i>-Tetradecanoylphorbol 13-Acetate, and Analysis of the Role of Histamine in the Modified Model

Hirasawa

Ohsawa

Katoh

et al. 2008

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: In atopic dermatitis, inflammation induced by antigen-nonspecific stimuli further enhances the allergic inflammation. However, there is no experimental model in which allergic dermatitis is evoked where the inflammation has been induced by antigen-nonspecific stimuli. Here, we established a novel dermatitis model in mice and analyzed the role of histamine. Methods: After sensitization with picryl chloride (PiCl) by painting on ear lobes of cyclophosphamide-treated mice, 12-O-tetradecanoylphorbol 13-acetate (TPA) was painted twice at the same site, and then allergic inflammation was induced by painting PiCl. Histamine antagonists and cyclosporine A (CsA) were administered intravenously. Results: The application of TPA shifted the PiCl-induced allergic inflammation from a delayed-type response to a biphasic response, increased the infiltration of eosinophils and mast cells at the inflammatory site, shifted the cytokine milieu from Th1 to Th2 and induced the expression of thymic stromal lymphopoietin in the ear lobes. The PiCl-induced increase in the thickness of the ear lobe in the immediate phase was suppressed by the H1 antagonist pyrilamine. In contrast, the increase in the swelling in the late phase and the infiltration of eosinophils were suppressed by the H3/H4 antagonist thioperamide. The inhibitory effect of the combined treatment with pyrilamine and thioperamide on the TPA-modified contact dermatitis was as potent as that of CsA. Conclusion: Induction of the antigen-nonspecific inflammation by TPA enhanced the PiCl-induced allergic inflammation. Histamine plays significant roles in the early-phase swelling via H1 receptors, and the late-phase swelling via H3/H4 receptors in this TPA-modified allergic dermatitis model.

show abstract

Section: Discussionsupporting

confidence: 72%

Modification of the Picryl Chloride-Induced Allergic Dermatitis Model in Mouse Ear Lobes by 12-<i>O</i>-Tetradecanoylphorbol 13-Acetate, and Analysis of the Role of Histamine in the Modified Model

Hirasawa

Ohsawa

Katoh

et al. 2008

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…These drugs inhibit the production of cytokines (24) and the antigeninduced degranulation of mast cells and basophils (25,26) and thereby suppress allergic dermatitis (23,27). In our model, we confirmed that cyclosporin A inhibits the swelling of the ear lobe in both the immediate-phase and late-phase (Fig.…”

Section: Roles Of Histaminesupporting

confidence: 74%

Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Establishment of a Modified Allergic Dermatitis Model in Mouse Ear Lobes by Application of 12-O-Tetradecanoyl Phorbol 13-Acetate: Putative Involvement of Thymic Stromal Lymphopoietin and Roles of Histamine

et al. 2009

View full text Add to dashboard Cite

Abstract. We established a novel allergic dermatitis model in mouse ear lobes in which antigen-nonspecific inflammation was induced by painting 12-O-tetradecanoylphorbol 13-acetate (TPA) between sensitization and challenge with picryl chloride (PiCl). This model has an advantage for analyzing atopic dermatitis-like inflammation within a short period. Analysis of the time course changes in the PiCl-induced swelling showed that the allergic inflammation was shifted from a delayed-type response to a biphasic response consisting of a weak immediatephase response and a late-phase response by painting with TPA. The application of TPA increased the PiCl-induced infiltration of eosinophils and mast cells at the inflammatory site and shifted the cytokine milieu from Th1 to Th2. The expression of the Th2-inducing cytokine thymic stromal lymphopoietin (TSLP) mRNA was also increased by TPA. These findings suggested that the induction of antigen-nonspecific inflammation by TPA before the antigen challenge enhanced the Th2 response and modified the PiCl-induced delayed type-hypersensitivity. Using this model, we clarified that histamine plays significant roles in the early-phase swelling via H 1 receptors and the late-phase swelling via H 3 /H 4 receptors. Thus, we suggested the usefulness of the combined treatment with an H 1 antagonist and an H 4 antagonist for the suppression of atopic dermatitis.

show abstract

“…Upon keratinocytes, FK506 upregulated transforming growth factor-(TGF-) produc-*Address correspondence to this author at the Department of Dermatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295 (Japan); Tel: +81 24 547 1307; Fax: +81 24 548 5412; E-mail: toyamade@fmu.ac.jp tion, downregulated inducible nitric oxide synthase (iNOS) production [10], and inhibited TNF-secretion via regulation of NF-kB [11]. Other studies showed that topical tacroimus therapy reduced the expresson of adhesion molecules [12] and some chemokines which recruits eosinophils [13] in the lesional skin of atopic dermatitis.…”

Section: Pharmacology Of Tacrolimusmentioning

confidence: 99%

Topical Tacrolimus for Psoriasis

Yamamoto¹

2009

TOALLJ

View full text Add to dashboard Cite

Tacrolimus ointment is an agent approved for the treatment of atopic dermatitis; however, tacrolimus has been expected also as one of the promising therapeutic strategies for other T-cell mediated inflammatory skin disorders. Recent progress have demonstrated that topical tacrolimus shows beneficial effects for psoriasis depending on sites. In particular, facial, intertriginous, and genital psoriasis respond to topical tacrolimus dramatically in a short period. Further, topical tacrolimus is tolerable also for child psoriasis. Because topical tacrolimus does not induce either skin atrophy or telangiectasia different from corticosteroids, it is recommended to be a first choice. The most proper way of topical tacrolimus therapy at present is to use this ointment intermittently after the remission was once obtained, paying attention to its adverse effects.

show abstract

Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.

Abstract: Topical tacrolimus reduces the number of eosinophils in tissue and suppresses the expression of eotaxin, CCR3, RANTES and IL-5 related to proliferation, recruitment, activation and survival of eosinophils.

Cited by 50 publications

References 36 publications

Modification of the Picryl Chloride-Induced Allergic Dermatitis Model in Mouse Ear Lobes by 12-<i>O</i>-Tetradecanoylphorbol 13-Acetate, and Analysis of the Role of Histamine in the Modified Model

Modification of the Picryl Chloride-Induced Allergic Dermatitis Model in Mouse Ear Lobes by 12-<i>O</i>-Tetradecanoylphorbol 13-Acetate, and Analysis of the Role of Histamine in the Modified Model

Topical Tacrolimus for Psoriasis

Contact Info

Product

Resources

About